查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1944390

全球药物定序市场：按部署方法、治疗领域、最终用途、药物分子、方法类型、给药途径、国家和地区划分－产业分析、市场规模、份额和预测（2025-2032）

Drug Repurposing Market, By Deployment Mode, By Therapeutic Area, By End Use, By Drug Molecules, By Type of Approach, By Route of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 349 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2024 年，现有药物定序市场价值将达到 330.181 亿美元，从 2025 年到 2032 年的复合年增长率将达到 4.30%。

药物定序市场专注于识别和开发现有或已获核准药物的新治疗用途，与传统药物研发方法相比，能够更快、更经济高效地开发治疗方法。研发成本的不断攀升以及加速复杂罕见疾病治疗方法的迫切需求是推动市场成长的主要因素。人工智慧 (AI) 和真实世界数据在发现新型药物-疾病关联的应用日益广泛，是该市场的关键趋势。然而，监管的不确定性、智慧财产权限制以及资料检验方面的挑战都构成了重大障碍。儘管存在这些障碍，但对罕见疾病、肿瘤和新兴感染疾病的日益关注为药物定序提供了巨大的机会，它可以缩短研发週期、降低失败风险并最大限度地发挥现有药物资产的临床价值。

药物定序的市场动态

医疗保健成本上升推动药物定序市场成长

全球医疗保健支出不断增长是推动药物定序市场发展的主要动力。医疗保健支出涵盖预防、诊断、治疗、復健和医疗保健管理等各个方面，由于医疗成本上升、技术进步以及对医疗服务需求的不断增长，医疗保健支出持续攀升。不断增长的医疗支出促使人们增加对研究活动、临床试验和数据驱动型研究的投资，而这些对于发现现有药物的新治疗适应症至关重要。这一趋势极大地促进了药物定序，因为它提供了一种比传统药物研发成本更低、速度更快的替代方案。根据美国医疗保险和医疗补助服务中心于2022年3月发布的《2021-2030年国家医疗保健支出报告》，预计到2030年，美国国家医疗保健支出将以每年平均5.1%的速度增长，达到约6.8兆美元。不断增长的医疗保险和医疗补助支出将有助于为药物再利用研究提供资金，从而加速市场扩张。

药物定序市场：細項分析

全球药物定序市场按引入方式、治疗领域、最终用途、药物分子、方法类型、给药途径和地区进行细分。

肿瘤治疗占据了相当大的市场份额，这主要得益于全球癌症高发病率以及对更有效、更易获得的治疗方案的巨大未满足需求。现有的癌症药物或最初核准用于非肿瘤适应症的治疗方法，正越来越多地被评估用于新的癌症治疗，其依据是已确立的安全性和有效性，从而缩短了研发週期。这项策略显着降低了新癌症疗法的研发成本和所需时间。例如，2024年12月，德州大学西南医学中心的研究人员报告称，一种获得FDA核准用于治疗多发性骨髓瘤和淋巴瘤的药物，在KRAS突变型非小细胞肺癌患者中显示出肿瘤消退的现象。同时，诸如ReDO计划等措施正在推动非肿瘤药物的再利用，用于肿瘤治疗，重点在于提供有效且低毒性的治疗方案。

按最终用途划分，製药和生物技术公司占据了大部分收入份额。这些公司拥有完善的基础设施、强大的研发能力和丰富的监管经验，使其能够有效地将现有药物用于新的适应症。它们雄厚的财力有助于资金筹措临床试验和收购有前景的候选药物。此外，日益增长的医疗保健缺口需求和对低成本治疗方法的需求也促使这些公司考虑药物再利用策略。 2022年5月，美国食品药物管理局（FDA）核准Baricitinib用于治疗需要不同程度呼吸支持的COVID-19住院成人患者。此前， 核准于2020年11月发布了紧急使用授权（EUA），授权Baricitinib替尼联合治疗瑞德西韦用于治疗COVID-19住院成人和儿童患者。此次核准基于适应性COVID-19治疗试验（ACTT-2）的结果，该试验表明，联合治疗缩短了住院患者的康復时间并改善了临床疗效。

药物定序市场—区域分析

北美市场主导。这一增长得益于先进的研究基础设施、有利的监管环境以及对老药新用药物的快速核准。此外，该地区还促进了人工智慧Start-Ups、研究中心和大型製药企业之间的紧密合作，共同开发针对各种疾病的老药新用药物。 2025年8月，Fifty 1 Labs, Inc.的子公司Fifty 1 AI Labs与LUNR Aerospace合作，共同开发一项用于太空医学的人工智慧驱动型药物定序倡议。

美国药物定序市场—国家分析

美国是北美的重要市场，其蓬勃发展的製药和生技产业正推动着对人工智慧驱动的药物研发平台的投资。例如，总部位于麻萨诸塞州的Lyra Sciences公司于2025年9月完成了2.35亿美元的A轮资金筹措，用于扩展其人工智慧驱动的自主实验室。这笔资金将用于扩建Lyra位于波士顿、旧金山和伦敦的「人工智慧科学工厂」。在这些工厂中，人工智慧模型能够提出假设、运行实验、从结果中学习，并不断迭代，直到整个流程完成。美国良好的资金筹措环境，以及学术机构与人工智慧解决方案供应商之间成熟的合作关係，持续推动大规模的再利用计画。

目录

第一章：药物定序市场概览

  • 分析范围
  • 市场估算期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章：药物定序的主要市场趋势

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 未来市场趋势

4. 药物定序市场：产业分析

  • PEST分析
  • 波特五力分析
  • 市场成长展望：概览
  • 管理体制分析

第五章 药物定序市场：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：药物定序市场现状

  • 药物定序市占率分析（2024 年）
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

第七章 依部署方式分類的药物定序市场

  • 概述
    • 按部署模式分類的细分市场占有率分析
    • 本地部署
    • 基于云端的

8. 按治疗领域分類的药物定序市场

  • 概述
    • 细分市场占有率分析：依治疗领域划分
    • 肿瘤学
    • 循环系统疾病
    • 感染疾病
    • 罕见疾病
    • 神经病学
    • 免疫学
    • 代谢性疾病
    • 其他的

9. 按最终用途分類的药物定序市场

  • 概述
    • 细分市场占有率分析：依最终用途划分
    • CRO（委外研发机构）
    • 製药和生物技术公司
    • 医疗保健提供者
    • 学术和研究机构
    • 其他的

10. 依药物分子分类的药物定序市场

  • 概述
    • 细分市场占有率分析：依药物分子划分
    • 胜肽
    • 生物製药
    • 疫苗
    • 常规小分子化合物
    • 其他的

第十一章：依方法类型分類的药物定序市场

  • 概述
    • 细分市场占有率分析：依方法类型
    • 以目标为中心
    • 以疾病为中心
    • 以药物为中心

第十二章：按给药途径分類的药物定序市场

  • 概述
    • 细分市场占有率分析：依管理途径
    • 静脉注射
    • 口服
    • 其他给药途径

第十三章 各地区的药物定序市场

  • 介绍
  • 北美洲
    • 概述
    • 北美主要製造商
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲主要製造商
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他的
  • 亚太地区
    • 概述
    • 亚太地区主要製造商
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他的
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他的
  • 中东和非洲
    • 概述
    • 中东和非洲的主要製造商
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他的

第十四章 主要供应商分析－药物定序产业

  • 竞争对手仪錶板
    • 竞争基准
    • 竞争定位
  • 公司简介
    • Eli Lilly and Company
    • GSK plc
    • Amgen Inc.
    • Biogen Inc.
    • Pfizer Inc.
    • Roche Holding AG
    • Novartis AG
    • AbbVie
    • Amgen
    • Boehringer Ingelheim
    • Cyclica
    • GlaxoSmithKline
    • Vertex Pharmaceuticals
    • Melior Discovery
    • Pharnext
    • Recursion Pharmaceuticals
    • Revolution Medicines
    • Sanofi
    • Schwarz Pharma
    • Valence Discovery
    • Bayer AG
    • Teva Pharmaceutical
    • Others

第十五章 AnalystView 360度分析

简介目录
Product Code: ANV5994

Drug Repurposing Market size was valued at US$ 33,018.10 Million in 2024, expanding at a CAGR of 4.30% from 2025 to 2032.

The drug repurposing market focuses on identifying and developing new therapeutic uses for existing or previously approved drugs, allowing for faster and more cost-effective treatment development than traditional drug discovery. Rising R&D costs and the urgent need to accelerate therapies for complex and rare diseases are the primary drivers of market growth. The increasing use of artificial intelligence and real-world data to discover novel drug-disease relationships is a major market trend. However, regulatory uncertainties, intellectual property limitations, and data validation challenges all act as significant barriers. Despite these obstacles, a greater emphasis on rare diseases, oncology, and emerging infectious conditions presents significant opportunities for drug repurposing, which reduces development timelines, lowers failure risk, and maximizes the clinical value of existing pharmaceutical assets.

Drug Repurposing Market- Market Dynamics

Rising Healthcare Expenditure Driving Drug Repurposing Market Growth

The increasing level of global healthcare expenditure is a major driver of the drug repurposing market's growth. Healthcare spending includes prevention, diagnosis, treatment, rehabilitation, and healthcare administration, and it is increasing due to rising medical costs, technological advancements, and increased demand for healthcare services. Increased healthcare spending allows for more investment in research activities, clinical trials, and data-driven studies, all of which are critical for discovering new therapeutic indications for existing drugs. This trend benefits drug repurposing significantly because it provides a less expensive and faster alternative to traditional drug discovery. According to the 2021-2030 National Health Expenditure report published by the United States Centers for Medicare & Medicaid Services in March 2022, national health spending is expected to increase at an average annual rate of 5.1%, reaching nearly USD 6.8 trillion by 2030. Rising Medicare and Medicaid spending boosts funding availability for repurposing research, hastening market expansion.

Drug Repurposing Market- Segmentation Analysis:

The Global Drug Repurposing Market is segmented on the basis of Deployment Mode, Therapeutic Area, End Use, Drug Molecules, Type of Approach, Route of Administration, and Region.

Oncology represents a significant share of the market, driven by the high global prevalence of cancer and the substantial unmet need for more effective and accessible treatment options. A growing number of existing oncology drugs, as well as therapies originally approved for non-oncologic indications, are being evaluated for new cancer applications by leveraging their established safety and efficacy profiles to accelerate development timelines. This strategy significantly reduces both the cost and time required to introduce new cancer treatments. For example, in December 2024, researchers at UT Southwestern reported that an FDA-approved therapy for multiple myeloma and lymphoma demonstrated tumor-shrinking effects in patients with KRAS-mutated non-small cell lung cancer. In parallel, initiatives such as the ReDO Project are advancing the repurposing of non-cancer drugs for oncology, with a focus on delivering effective, low-toxicity treatment alternatives.

Based on End Use, Pharmaceutical and biotechnology companies account for the majority of revenue share. These companies have established infrastructure, extensive R&D capabilities, and regulatory expertise, allowing them to effectively repurpose existing drugs for new indications. Their vast financial resources make it easier to fund clinical trials and acquire promising drug candidates. Furthermore, the growing need to fill gaps in medical care and the demand for low-cost therapies have prompted these companies to investigate repurposing strategies. The United States Food and Drug Administration (FDA) approved baricitinib in May 2022 for the treatment of hospitalized adults who require varying degrees of respiratory support as a result of COVID-19. This approval followed an earlier Emergency Use Authorization (EUA) issued in November 2020 for the combination of baricitinib and remdesivir in the treatment of COVID-19 in hospitalized adults and pediatric patients. The approval was based on results from the Adaptive COVID-19 Treatment Trial (ACTT-2), which showed that the combination therapy shortened recovery time and improved clinical outcomes in hospitalized patients..

Drug Repurposing Market- Geographical Insights

North America dominates the market. The expansion is fueled by advanced research infrastructure, supportive regulatory landscapes, and faster approval for repurposed drugs. In addition, this region is promoting strong collaborations between AI startups, research centers, and large pharmaceutical companies to develop repurposed drugs for various diseases. In August 2025, Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc., collaborated with LUNR Aerospace to develop AI-powered drug repurposing initiatives for space medicine.

United States Drug Repurposing Market- Country Insights

The United States is the major North American market, driven by a thriving pharmaceutical and biotechnology industry that is investing in AI-powered drug discovery platforms. For example, in September 2025, Massachusetts-based Lila Sciences raised USD 235 million in a Series A round to expand its AI-powered autonomous laboratories. The funds are raised to expand Lila's "AI Science Factories" in Boston, San Francisco, and London, where AI models develop hypotheses, run experiments, learn from results, and iterate from start to finish. The nation's strong financing environment, combined with mature collaborations between academia and AI solution providers, continues to drive large-scale repurposing programs.

Drug Repurposing Market- Competitive Landscape:

The drug repurposing market is distinguished by collaborations among pharmaceutical companies, biotech firms, research institutions, and technology providers aimed at discovering new therapeutic applications for existing medications. Strategic partnerships, licensing agreements, and investments in advanced computational platforms that accelerate drug repurposing research all have an impact on competition. Companies are increasingly relying on artificial intelligence, real-world evidence, and big data analytics to improve target identification, streamline clinical validation, and lower development costs. Regulatory alignment and shared research frameworks also have an impact on competitive positioning. Novartis AG, Pfizer Inc., Eli Lilly and Company, and Bayer AG are key players driving innovation and commercial activity in the drug repurposing market. These organizations use extensive compound libraries, global R&D capabilities, and strategic alliances to broaden their repurposed drug portfolios and increase market visibility.

In April 2025, Novartis agreed to acquire Regulus Therapeutics, a San Diego-based clinical-stage biopharmaceutical company focused on microRNA therapies. Faburden, Regulus' leading asset, targets miR-17 and has the potential to be a first-in-class treatment for autosomal dominant polycystic kidney disease (ADPKD). This acquisition complements Novartis' focus on renal disease and will increase its expertise in this therapeutic area. The acquisition expands Novartis' portfolio by incorporating novel approaches to treating kidney diseases.

Recent Developments:

In April 2025, Qualthera Health Corporation, which is dedicated to establishing a nationwide network of quality, patient-centered compounding pharmacies, has announced the official launch of Qualthera Pharmaceuticals Ltd. Co., a research-driven subsidiary focused on drug repurposing and innovative delivery systems. This expansion is a significant step forward in accelerating pharmaceutical innovation by leveraging real-world patient insights to create new therapies with streamlined development.

In June 2024, BioXcel Therapeutics used artificial intelligence-based drug repurposing to discover new applications for drug candidates that had stalled in development. The company accelerates therapeutic innovation by integrating approved and established drugs, clinically validated candidates, big data, and proprietary machine learning algorithms. It is focused on research and development costs, market access, and growth in neurology and immuno-oncology within the drug repurposing market.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DRUG REPURPOSING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Eli Lilly and Company
  • GSK plc
  • Amgen Inc.
  • Biogen Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • AbbVie
  • Amgen
  • Boehringer Ingelheim
  • Cyclica
  • GlaxoSmithKline
  • Vertex Pharmaceuticals
  • Melior Discovery
  • Pharnext
  • Recursion Pharmaceuticals
  • Revolution Medicines
  • Sanofi
  • Schwarz Pharma
  • Valence Discovery
  • Bayer AG
  • Teva Pharmaceutical
  • Others

GLOBAL DRUG REPURPOSING MARKET, BY DEPLOYMENT MODE- MARKET ANALYSIS, 2019 - 2032

  • On-premises
  • Cloud-based

GLOBAL DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Oncology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Rare Diseases
  • Neurology
  • Immunology
  • Metabolic Disorders
  • Others

GLOBAL DRUG REPURPOSING MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032

  • Contract Research Organizations (CROs)
  • Pharmaceutical & Biotechnology Companies
  • Healthcare Providers
  • Academic & Research Institutes
  • Others

GLOBAL DRUG REPURPOSING MARKET, BY DRUG MOLECULES- MARKET ANALYSIS, 2019 - 2032

  • Peptides
  • Biologics
  • Vaccines
  • Conventional Small Molecules
  • Others

GLOBAL DRUG REPURPOSING MARKET, BY TYPE OF APPROACH- MARKET ANALYSIS, 2019 - 2032

  • Target-centric
  • Disease-centric
  • Drug-centric

GLOBAL DRUG REPURPOSING MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous
  • Oral
  • Other routes of administration

GLOBAL DRUG REPURPOSING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Drug Repurposing Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Drug Repurposing Market Snippet by Deployment Mode
    • 2.1.2. Drug Repurposing Market Snippet by Therapeutic Area
    • 2.1.3. Drug Repurposing Market Snippet by End Use
    • 2.1.4. Drug Repurposing Market Snippet by Drug Molecules
    • 2.1.5. Drug Repurposing Market Snippet by Type of Approach
    • 2.1.6. Drug Repurposing Market Snippet by Route of Administration
    • 2.1.7. Drug Repurposing Market Snippet by Country
    • 2.1.8. Drug Repurposing Market Snippet by Region
  • 2.2. Competitive Insights

3. Drug Repurposing Key Market Trends

  • 3.1. Drug Repurposing Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Drug Repurposing Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Drug Repurposing Market Opportunities
  • 3.4. Drug Repurposing Market Future Trends

4. Drug Repurposing Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Drug Repurposing Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Drug Repurposing Market Landscape

  • 6.1. Drug Repurposing Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Drug Repurposing Market - By Deployment Mode

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Deployment Mode, 2024 & 2032 (%)
    • 7.1.2. On-premises
    • 7.1.3. Cloud-based

8. Drug Repurposing Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 8.1.2. Oncology
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Infectious Diseases
    • 8.1.5. Rare Diseases
    • 8.1.6. Neurology
    • 8.1.7. Immunology
    • 8.1.8. Metabolic Disorders
    • 8.1.9. Others

9. Drug Repurposing Market - By End Use

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End Use, 2024 & 2032 (%)
    • 9.1.2. Contract Research Organizations (CROs)
    • 9.1.3. Pharmaceutical & Biotechnology Companies
    • 9.1.4. Healthcare Providers
    • 9.1.5. Academic & Research Institutes
    • 9.1.6. Others

10. Drug Repurposing Market - By Drug Molecules

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Drug Molecules, 2024 & 2032 (%)
    • 10.1.2. Peptides
    • 10.1.3. Biologics
    • 10.1.4. Vaccines
    • 10.1.5. Conventional Small Molecules
    • 10.1.6. Others

11. Drug Repurposing Market - By Type of Approach

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Type of Approach, 2024 & 2032 (%)
    • 11.1.2. Target-centric
    • 11.1.3. Disease-centric
    • 11.1.4. Drug-centric

12. Drug Repurposing Market - By Route of Administration

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 12.1.2. Intravenous
    • 12.1.3. Oral
    • 12.1.4. Other routes of administration

13. Drug Repurposing Market- By Geography

  • 13.1. Introduction
    • 13.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 13.2. North America
    • 13.2.1. Overview
    • 13.2.2. Drug Repurposing Key Manufacturers in North America
    • 13.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.2.4. North America Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
    • 13.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 13.2.6. North America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 13.2.7. North America Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
    • 13.2.8. North America Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
    • 13.2.9. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.2.10. U.S.
      • 13.2.10.1. Overview
      • 13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.2.10.3. U.S. Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.2.10.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.2.10.5. U.S. Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.2.10.6. U.S. Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.2.10.7. U.S. Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.2.10.8. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.2.11. Canada
      • 13.2.11.1. Overview
      • 13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.2.11.3. Canada Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.2.11.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.2.11.5. Canada Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.2.11.6. Canada Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.2.11.7. Canada Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.2.11.8. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 13.3. Europe
    • 13.3.1. Overview
    • 13.3.2. Drug Repurposing Key Manufacturers in Europe
    • 13.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.3.4. Europe Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
    • 13.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 13.3.6. Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 13.3.7. Europe Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
    • 13.3.8. Europe Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
    • 13.3.9. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.10. Germany
      • 13.3.10.1. Overview
      • 13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.10.3. Germany Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.10.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.10.5. Germany Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.10.6. Germany Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.10.7. Germany Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.10.8. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.11. UK
      • 13.3.11.1. Overview
      • 13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.11.3. UK Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.11.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.11.5. UK Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.11.6. UK Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.11.7. UK Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.11.8. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.12. France
      • 13.3.12.1. Overview
      • 13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.12.3. France Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.12.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.12.5. France Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.12.6. France Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.12.7. France Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.12.8. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.13. Italy
      • 13.3.13.1. Overview
      • 13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.13.3. Italy Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.13.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.13.5. Italy Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.13.6. Italy Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.13.7. Italy Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.13.8. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.14. Spain
      • 13.3.14.1. Overview
      • 13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.14.3. Spain Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.14.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.14.5. Spain Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.14.6. Spain Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.14.7. Spain Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.14.8. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.15. The Netherlands
      • 13.3.15.1. Overview
      • 13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.15.3. The Netherlands Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.15.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.15.5. The Netherlands Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.15.6. The Netherlands Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.15.7. The Netherlands Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.15.8. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.16. Sweden
      • 13.3.16.1. Overview
      • 13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.16.3. Sweden Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.16.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.16.5. Sweden Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.16.6. Sweden Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.16.7. Sweden Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.16.8. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.17. Russia
      • 13.3.17.1. Overview
      • 13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.17.3. Russia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.17.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.17.5. Russia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.17.6. Russia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.17.7. Russia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.17.8. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.18. Poland
      • 13.3.18.1. Overview
      • 13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.18.3. Poland Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.18.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.18.5. Poland Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.18.6. Poland Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.18.7. Poland Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.18.8. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.3.19. Rest of Europe
      • 13.3.19.1. Overview
      • 13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.3.19.3. Rest of the Europe Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.3.19.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.3.19.5. Rest of the Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.3.19.6. Rest of the Europe Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.3.19.7. Rest of the Europe Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.3.19.8. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 13.4. Asia Pacific (APAC)
    • 13.4.1. Overview
    • 13.4.2. Drug Repurposing Key Manufacturers in Asia Pacific
    • 13.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.4.4. APAC Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
    • 13.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 13.4.6. APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 13.4.7. APAC Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
    • 13.4.8. APAC Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
    • 13.4.9. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.10. China
      • 13.4.10.1. Overview
      • 13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.10.3. China Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.10.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.10.5. China Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.10.6. China Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.10.7. China Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.10.8. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.11. India
      • 13.4.11.1. Overview
      • 13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.11.3. India Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.11.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.11.5. India Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.11.6. India Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.11.7. India Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.11.8. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.12. Japan
      • 13.4.12.1. Overview
      • 13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.12.3. Japan Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.12.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.12.5. Japan Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.12.6. Japan Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.12.7. Japan Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.12.8. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.13. South Korea
      • 13.4.13.1. Overview
      • 13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.13.3. South Korea Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.13.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.13.5. South Korea Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.13.6. South Korea Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.13.7. South Korea Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.13.8. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.14. Australia
      • 13.4.14.1. Overview
      • 13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.14.3. Australia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.14.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.14.5. Australia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.14.6. Australia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.14.7. Australia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.14.8. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.15. Indonesia
      • 13.4.15.1. Overview
      • 13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.15.3. Indonesia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.15.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.15.5. Indonesia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.15.6. Indonesia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.15.7. Indonesia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.15.8. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.16. Thailand
      • 13.4.16.1. Overview
      • 13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.16.3. Thailand Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.16.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.16.5. Thailand Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.16.6. Thailand Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.16.7. Thailand Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.16.8. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.17. Philippines
      • 13.4.17.1. Overview
      • 13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.17.3. Philippines Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.17.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.17.5. Philippines Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.17.6. Philippines Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.17.7. Philippines Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.17.8. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.4.18. Rest of APAC
      • 13.4.18.1. Overview
      • 13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.4.18.3. Rest of APAC Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.4.18.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.4.18.5. Rest of APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.4.18.6. Rest of APAC Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.4.18.7. Rest of APAC Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.4.18.8. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 13.5. Latin America (LATAM)
    • 13.5.1. Overview
    • 13.5.2. Drug Repurposing Key Manufacturers in Latin America
    • 13.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.5.4. LATAM Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
    • 13.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 13.5.6. LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 13.5.7. LATAM Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
    • 13.5.8. LATAM Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
    • 13.5.9. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.10. Brazil
      • 13.5.10.1. Overview
      • 13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.10.3. Brazil Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.5.10.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.5.10.5. Brazil Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.5.10.6. Brazil Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.5.10.7. Brazil Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.5.10.8. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.11. Mexico
      • 13.5.11.1. Overview
      • 13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.11.3. Mexico Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.5.11.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.5.11.5. Mexico Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.5.11.6. Mexico Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.5.11.7. Mexico Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.5.11.8. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.12. Argentina
      • 13.5.12.1. Overview
      • 13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.12.3. Argentina Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.5.12.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.5.12.5. Argentina Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.5.12.6. Argentina Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.5.12.7. Argentina Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.5.12.8. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.13. Colombia
      • 13.5.13.1. Overview
      • 13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.13.3. Colombia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.5.13.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.5.13.5. Colombia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.5.13.6. Colombia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.5.13.7. Colombia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.5.13.8. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.5.14. Rest of LATAM
      • 13.5.14.1. Overview
      • 13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.5.14.3. Rest of LATAM Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.5.14.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.5.14.5. Rest of LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.5.14.6. Rest of LATAM Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.5.14.7. Rest of LATAM Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.5.14.8. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 13.6. Middle East and Africa
    • 13.6.1. Overview
    • 13.6.2. Drug Repurposing Key Manufacturers in Middle East and Africa
    • 13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 13.6.4. Middle East and Africa Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
    • 13.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 13.6.6. Middle East and Africa Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 13.6.7. Middle East and Africa Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
    • 13.6.8. Middle East and Africa Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
    • 13.6.9. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.10. Saudi Arabia
      • 13.6.10.1. Overview
      • 13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.10.3. Saudi Arabia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.10.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.10.5. Saudi Arabia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.10.6. Saudi Arabia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.10.7. Saudi Arabia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.10.8. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.11. United Arab Emirates
      • 13.6.11.1. Overview
      • 13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.11.3. United Arab Emirates Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.11.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.11.5. United Arab Emirates Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.11.6. United Arab Emirates Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.11.7. United Arab Emirates Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.11.8. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.12. Israel
      • 13.6.12.1. Overview
      • 13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.12.3. Israel Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.12.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.12.5. Israel Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.12.6. Israel Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.12.7. Israel Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.12.8. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.13. Turkey
      • 13.6.13.1. Overview
      • 13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.13.3. Turkey Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.13.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.13.5. Turkey Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.13.6. Turkey Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.13.7. Turkey Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.13.8. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.14. Algeria
      • 13.6.14.1. Overview
      • 13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.14.3. Algeria Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.14.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.14.5. Algeria Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.14.6. Algeria Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.14.7. Algeria Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.14.8. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.15. Egypt
      • 13.6.15.1. Overview
      • 13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.15.3. Egypt Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.15.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.15.5. Egypt Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.15.6. Egypt Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.15.7. Egypt Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.15.8. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 13.6.16. Rest of MEA
      • 13.6.16.1. Overview
      • 13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 13.6.16.3. Rest of MEA Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
      • 13.6.16.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 13.6.16.5. Rest of MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
      • 13.6.16.6. Rest of MEA Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
      • 13.6.16.7. Rest of MEA Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
      • 13.6.16.8. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)

14. Key Vendor Analysis- Drug Repurposing Industry

  • 14.1. Competitive Benchmarking
    • 14.1.1. Competitive Dashboard
    • 14.1.2. Competitive Positioning
  • 14.2. Company Profiles
    • 14.2.1. Eli Lilly and Company
    • 14.2.2. GSK plc
    • 14.2.3. Amgen Inc.
    • 14.2.4. Biogen Inc.
    • 14.2.5. Pfizer Inc.
    • 14.2.6. Roche Holding AG
    • 14.2.7. Novartis AG
    • 14.2.8. AbbVie
    • 14.2.9. Amgen
    • 14.2.10. Boehringer Ingelheim
    • 14.2.11. Cyclica
    • 14.2.12. GlaxoSmithKline
    • 14.2.13. Vertex Pharmaceuticals
    • 14.2.14. Melior Discovery
    • 14.2.15. Pharnext
    • 14.2.16. Recursion Pharmaceuticals
    • 14.2.17. Revolution Medicines
    • 14.2.18. Sanofi
    • 14.2.19. Schwarz Pharma
    • 14.2.20. Valence Discovery
    • 14.2.21. Bayer AG
    • 14.2.22. Teva Pharmaceutical
    • 14.2.23. Others

15. 360 Degree Analyst View

16. Appendix

  • 16.1. Research Methodology
  • 16.2. References
  • 16.3. Abbreviations
  • 16.4. Disclaimer
  • 16.5. Contact Us